245 related articles for article (PubMed ID: 32974848)
21. F-18 fluoride uptake in primary breast cancer.
Sarikaya I; Sharma P; Sarikaya A
Ann Nucl Med; 2018 Dec; 32(10):678-686. PubMed ID: 30178199
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
[TBL] [Abstract][Full Text] [Related]
23. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
24. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes.
Mavi A; Urhan M; Yu JQ; Zhuang H; Houseni M; Cermik TF; Thiruvenkatasamy D; Czerniecki B; Schnall M; Alavi A
J Nucl Med; 2006 Sep; 47(9):1440-6. PubMed ID: 16954551
[TBL] [Abstract][Full Text] [Related]
25. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
26. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of the Volumetric Parameters of Dual-Time-Point
Okazaki E; Seura H; Hasegawa Y; Okamura T; Fukuda H
AJR Am J Roentgenol; 2019 Dec; 213(6):1366-1373. PubMed ID: 31509426
[No Abstract] [Full Text] [Related]
28. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer.
Arslan E; Çermik TF; Trabulus FDC; Talu ECK; Başaran Ş
Nucl Med Commun; 2018 Jul; 39(7):680-690. PubMed ID: 29893750
[TBL] [Abstract][Full Text] [Related]
29. Increased FDG uptake in breast cancer is associated with prognostic factors.
Sanli Y; Kuyumcu S; Ozkan ZG; Işik G; Karanlik H; Guzelbey B; Turkmen C; Ozel S; Yavuz E; Mudun A
Ann Nucl Med; 2012 May; 26(4):345-50. PubMed ID: 22359222
[TBL] [Abstract][Full Text] [Related]
30. Physiological 18F-FDG uptake in the normal adult anal canal: evaluation by PET/CT.
Sena Y; Matsumoto S; Silman C; Otsuka K; Kiyota T
Ann Nucl Med; 2020 Aug; 34(8):538-544. PubMed ID: 32430619
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of dual time point F-18 FDG PET imaging for grading of brain tumors.
Kim DW; Jung SA; Kim CG; Park SA
Clin Nucl Med; 2010 Jun; 35(6):400-3. PubMed ID: 20479584
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of dual-time
Pahk K; Chung JH; Kim S; Lee SH
Tumori; 2018 Jun; 104(3):207-212. PubMed ID: 29714664
[TBL] [Abstract][Full Text] [Related]
33. Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors.
Karan B; Pourbagher A; Torun N
J Magn Reson Imaging; 2016 Jun; 43(6):1434-44. PubMed ID: 26663655
[TBL] [Abstract][Full Text] [Related]
34. Background ¹⁸F-FDG uptake in positron emission mammography (PEM): correlation with mammographic density and background parenchymal enhancement in breast MRI.
Koo HR; Moon WK; Chun IK; Eo JS; Jeyanth JX; Chang JM; Cho N; Kang KW
Eur J Radiol; 2013 Oct; 82(10):1738-42. PubMed ID: 23806533
[TBL] [Abstract][Full Text] [Related]
35. A new method for apparent diffusion coefficient measurement using sequential (18)F-FDG PET and MRI: correlation with histological grade of invasive ductal carcinoma of the breast.
Byun BH; Noh WC; Lim I; Lee SS; Cho AR; Park JA; Kim KM; Kim HA; Kim EK; Kim BI; Choi CW; Lim SM
Ann Nucl Med; 2013 Oct; 27(8):720-8. PubMed ID: 23700260
[TBL] [Abstract][Full Text] [Related]
36. More accurate than MRI measurement of tumor size in breast cancer by using the peri-tumoral halo uptake layer method of the
Park SH; Seo M; Choi HJ; Bae K; Bang M; Jun S
Hell J Nucl Med; 2018; 21(2):108-114. PubMed ID: 30006644
[TBL] [Abstract][Full Text] [Related]
37. Correlation of
Mitamura K; Yamamoto Y; Norikane T; Hatakeyama T; Okada M; Nishiyama Y
Ann Nucl Med; 2018 Nov; 32(9):627-633. PubMed ID: 30032455
[TBL] [Abstract][Full Text] [Related]
38. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer.
Goense L; Heethuis SE; van Rossum PSN; Voncken FEM; Lagendijk JJW; Lam MGEH; Terhaard CH; van Hillegersberg R; Ruurda JP; Mook S; van Lier ALHMW; Lin SH; Meijer GJ
Nucl Med Commun; 2018 Jan; 39(1):60-67. PubMed ID: 29023336
[TBL] [Abstract][Full Text] [Related]
39. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
[TBL] [Abstract][Full Text] [Related]
40. Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer.
Baun C; Falch K; Gerke O; Hansen J; Nguyen T; Alavi A; Høilund-Carlsen PF; Hildebrandt MG
BMC Med Imaging; 2018 May; 18(1):11. PubMed ID: 29743027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
